Hypolipidemics Flashcards

1
Q

What is the mechanism of action of Niacin?

A

Reduction of liver triglyceride synthesis–leading to less hepatic VLDL production
Decreases lipolysis in adipose tissue–leading to lowered FFA transport to liver
Reduced hepatic clearance of APOAI–raising HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the uses of Niacin?

A

Best agent to increase HDL
As good as vibrates and statins at lowering triglycerides
Lowers LDL
Hypertriglyceridemia and low HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the side effects of Niacin?

A

Flushing
Pruritis of face and upper trunk
Rashes
Acanthosis nigricans–hyperpigmentation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The use of Niacin is contraindicated in?

A

DM and gout pts

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Name the fabric acid derivatives (Fibrates)

A

Clofibrate
Gemfibrozil
Fenofibrate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the mechanism of action of the fibrates?

A

Interacts with peroxisome proliferator activated receptor–PPARa to stimulate LPL synthesis –enhancing TG-rich lipoprotein clearance

Inhibits apoC III expression–enhancing VLDL clearance

Stimulation of apoAI and apoAII–increasing HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are the uses of the fibrates?

A

Reduction in VLDL–thus triglycerides
Little effect on LDL
small increase in HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What are the side effects of the fibrates?

A

Potentiate oral anticoagulants
increase bile lithogenicity
Myositis flu-like syndrome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Name the bile acid sequestrants

A

Colestipol
Cholestyramine
Colesevelam

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the mechanism of action of the bile acid sequestrants?

A

Very positively charged resins binds negative charged bile acids–inhibiting reabsorption and increasing cholesterol loss

Leads to increase in LDL receptors in liver–to make more cholesterol–decreasing LDL in blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What do the bile acid sequestrants do?

A

Decrease LDL

Slight increase in TG and HDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the side effects of the bile acid sequestrants?

A

Very safe –Only hypolipidemic indicated for children

Impaired fat soluble vitamin absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When are the bile acid sequestrants contraindicated?

A

in hypertriglyceridemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the mechanism of action of the statins?

A

Inhibit HMG-CoA reductase formation of mevalonate

  • -leads to activation of SREBP–a membrane-bound transcription factor that increases LDL-R synthesis and lessen degradation
  • -reduction in cholesterol decreases VLDL synthesis–lowering TG
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What do the statins cause?

A

Reduce LDL and TG while increasing HDL

Used in the tx of dyslipidemia–reduces fatal and nonfatal CHD and strokes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the newer statins with a longer half-life that allow them to be taken anytime of the day rather than at night like the older ones?

A

Atovastatin
Rosuvastatin
Pitavastatin

17
Q

Drug that inhibits enterocyte absorption of cholesterol in intestine?

A

Ezetimbe

18
Q

What is the mechanism of action of Ezetimbe?

A

Inhibits cholesterol absorption by enterocytes in jejunum leading to less cholesterol in chylomicrons–reduction in chylomicron remnant cholesterol delivery to liver

19
Q

What does ezetimbe cause?

A

Decreases LDL-C

20
Q

PCSK9 inhibitors that are 2nd line therapy for hypercholesterolemia not controlled by diet and statins?

A

Alirocumab and evolucumab

21
Q

What is the mechanism of action of Alirocumab and evolucumab?

A

Inhibits an endopeptidase–PCSK9 responsible for LDL-R degradation–results in higher numbers of LDL-Rs on hepatocytes